Kamada Ltd. (KMDA +0.5%) inks an agreement with Alvotech to commercialize the latter’s portfolio of six biosimilars in Israel, once approved. The first product, PF708 (branded as Bonsity), a biosimilar to Eli Lilly’s osteoporosis med Forteo (teriparatide), should be launched in 2022.
Financial terms are not disclosed.
On cue from its ASLAN004-stoked run-up, ASLAN Pharmaceuticals (ASLN +49.2%) commences a public offering of American Depositary Shares (ADSs). Price, volume and terms have yet to be announced.
The U.S. Federal Trade Commission (FTC) grants antitrust clearance for Amgen’s (AMGN -0.5%) previously announced collaboration with BeiGene (BGNE -0.6%) that includes a $2.7B investment (20.5% stake) in the Chinese biotech.
Aleafia Health (OTCQX:ALEAF) is up 4% in early trade in response to an order from a licensed producer in Canada for 2,840 kg of dried cannabis flower at $2.50 per gram for a total of $7.1M. The transaction, consisting of three shipments, will be completed before the end of next month.
Mylan N.V. (NASDAQ:MYL) and development partner Biocon Ltd. (OTC:BCNQY) announce the U.S. commercial launch of Ogivri (trastuzumab-dkst), a biosimilar to Roche’s (OTCQX:RHHBY) Herceptin.
Mylan owns exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand, the EU and European Free Trade Association countries. Biocon has co-exclusive rights with Mylan in the rest of the world.
